Kornimate/medical-research-clean huggingface dataset:
treatment outcome of vascular depression

Conditions: Depressive Disorder; Depression

Summary: this 12-week study will evaluate the effectiveness of sertraline (zoloft®) for treatment of depression associated with small vascular lesions in the brain (vascular depression).

major late life depression (lld) is an important health problem with a large and growing number of affected individuals. a significant subset of patients with lld, particularly those with vascular depression, have abnormalities in certain parts of the brain that are evident on mri scans and may be associated with poor acute and long-term response to antidepressant treatment. studies have also indicated that lld patients frequently have frontal lobe dysfunction. a longitudinal study with the antidepressant nortriptyline has demonstrated that frontal lobe dysfunction is associated with poor acute response and a greater risk for recurrence of lld. however, it is not known if this finding applies to other antidepressants. this study will be the first clinical trial to simultaneously test the effects of specific brain and psychological factors on course of response, remission rate, and other measures of health outcomes in people with lld. participants are treated with sertraline for 12 weeks. during this period, participants undergo cognitive testing, mri, electrocardiogram (ekg), and laboratory tests. study visits occur every 2 weeks.

Eligibility criteria:
inclusion criteria: 1. ages 60+ 2. dsm-iv criteria for mdd 3. hamilton depression rating scale score \>18 4. no mri contraindications, e.g. foreign metallic implants, pacemaker 5. medication free of any psychotropic drug except as otherwise noted for set washout period (see d.2.1) 6. mini mental status exam score \<21 7. no unstable medical disorders (requiring immediate medical attention) 8. ability to give informed consent 9. english speaking exclusion criteria: 1. age \<60 2. does not meet dsm-iv criteria for mdd 3. hamilton depression rating scale score \<18 4. mri contraindications e.g. foreign metallic implants, pacemaker 5. psychotropic drug use other than zolpidem and lorazepam, prn within 2 weeks of entry 6. mini mental status exam score \>21, or known primary neurological disorders including dementia of the alzheimer type, parkinson's disease, multiple sclerosis, seizure disorder. 7. unstable medical disorders, uncorrected hypothyroidism, or any condition that in the investigators opinion makes the patients unsuitable for a trial 8. cannot give informed consent 9. does not speak english
taurine supplementation on cognitive function in patients with diabetes

Conditions: Taurine; Cognitive Decline; Diabetes Mellitus

Summary: diabetes has become important risk factors for threatening human life and health. studies have shown that chronic hyperglycemia lead to microvascular brain injury. the more common types of dementia are alzheimer's disease (ad). cognitive dysfunction is a precursor to alzheimer's disease. mild cognitive impairment (mci) is a cognitive impairment between normal aging and dementia, mainly manifested as memory impairment, especially episode memory defects, but also named obstacles, but the overall cognitive function is normal, daily life ability is normal. studies have shown that middle-aged diabetic patients' cognitive ability will decline by about 19% in 20 years compared to people without diabetes. sulfur amino acid is the indispensable amino acid in mammals, and its metabolites include taurine, hydrogen sulfide (h2s) and sulfur dioxide (so2). taurine was first isolated more than 150 years ago from ox (taurus) bile. although the taurine can be synthesized in vivo by cysteine in the presence of cysteine dioxygenase, it is mainly acquired from dietary sources, such as eggs, meat, and seafood. h2s is a biologically relevant mediator and plays potential roles in several physiological processes and disease states in the body. h2s is synthesized from 2 sulfur-containing amino acids, l-cysteine andl-methionine, by the 3 enzymes,cystathionine-γ-lyase (cse), cystathionine-β-synthetase(cbs), and3-mercaptopyruvate sulfurtransferase (3-mst). previous studies have demonstrated that taurine and h2s may play important roles in the development of themicroangiopathy and lower extremity arterial occlusive.


Eligibility criteria:
inclusion criteria: * type 2 diabetes exclusion criteria: * type2 diabetes with acute diabetic complications. * type1 diabetes. * history of depression, schizophrenia or dementia. * history of cardio-cerebral vascular events, such as congestive heart failure, myocardial infarction or stroke within 3 months. * history of parkinson's diseases, head injury,toxic encephacopathy,epilepsy. * hypohepatia (ast or ast is twice higher than the upper limit) or history of hepatitis or cirrhosis, hepatic encephalopathy. * renal insufficiency (serum creatinine 1.5 times higher than the upper limit) or history of dialysis and nephritic syndrome. * acute infections, tumor, severe arrhythmia, mental disorders, alcohol or medicine addiction. * fertile woman without contraceptives. * any surgical or medical conditions that significantly influence absorption, distribution, metabolism or excretion of the intervention drugs. * allergic to or have contraindication to the intervention drugs.
ga-68 dota-toc of somatostatin positive malignancies

Conditions: Neuroendocrine Tumor; Paraganglioma; Carcinoid Tumors; Neuroblastoma

Summary: this phase i/ii trial studies how well gallium ga 68-dota-toc positron emission tomography (pet)/computed tomography (ct) or pet/magnetic resonance imaging (mri) works in imaging patients with somatostatin receptor positive tumors. gallium ga 68-dota-toc binds to somatostatin receptor positive tumors and can be seen using a pet scan. a pet scan uses a special camera to detect energy given off from gallium ga 68-dota-toc, to make detailed pictures of areas where material accumulates in the body. diagnostic procedures, such as gallium ga 68-dota-toc pet/ct or pet/mri, may help find and diagnose somatostatin receptor positive tumors and help plan the best treatment.

primary objectives: i. to determine if gallium ga 68-dota-toc (gallium-68 labeled dota-toc) results in the delineation of more lesions than with conventional imaging. secondary objectives: i. to determine if the incorporation of gallium (ga)-68 dota-toc pet/ct into the management decision making process results in a change in stage of the patient. outline: patients receive gallium ga 68-dota-toc intravenously (iv) over 1-2 minutes. within 55-70 minutes, patients then undergo a pet/ct scan over 30-40 minutes or a pet/mri scan over 50 minutes. after completion of study, patients are followed up for 2 weeks.

Eligibility criteria:
inclusion criteria: * known or suspected somatostatin receptor positive tumor such as carcinoid; neuroendocrine tumor; neuroblastoma; pheochromocytoma. supporting evidence may include mri, ct, biochemical markers, and or pathology report. * age \> 1. * karnofsky performance status of \> 50 (or eastern cooperative oncology group (ecog) / world health organization (who) equivalent). * not pregnant. a negative serum pregnancy test is required for all female subjects with childbearing potential. * ability to understand a written informed consent document, and the willingness to sign it. exclusion criteria: * hepatic enzymes 5 times greater than the upper limits of normal, serum creatinine \> 3.0 mg/dl (270 micromole per liter (um/l). * patients exceeding the weight limitations of the scanner or are not able to enter the bore of the pet /ct scanner due to bmi * inability to lie still for the entire imaging time (e.g. cough, severe arthritis, etc.); although at mission bay hospital pediatric patients may be sedated per clinical protocol. * inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.). * any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with study compliance. * recognized concurrent active infection previous systemic or radiation treatment for another cancer of any type within the last 2 months. * use of any other investigational product or device within 30 days prior to dosing, or known requirement for any other investigational agent prior to completion of all scheduled study assessments
urea therapy for hyponatremia in subarachnoid hemorrhage

Conditions: Hyponatremia; Subarachnoid Hemorrhage; SIADH

Summary: hyponatremia is defined as a plasma sodium concentration below 135 mmol / l. this is a common occurrence (20-50%) during subarachnoid hemorrhage (sah). its appearance is often associated with vasospasm. it is associated with an increase in morbidity and mortality linked to induced neurological disorders. hyponatremia is caused by two etiologies: the syndrome of inappropriate secretion of anti-diuretic hormone (siadh), and the cerebral salt wasting syndrome, csws. theoretically, these two entities are differentiated by the patient's volemia; in practice, this parameter is difficult to measure. in addition, the correction of hyponatremia is diametrically opposed according to its mechanism: water restriction in the case of siadh, sodium intake in the event of csws. urea is offered as a second-line treatment in the event of treatment failure to correct hyponatremia. however, the efficacy of this treatment is based on small, observational, retrospective studies. moreover, the mechanism of action of urea remains poorly understood: it could be a hyperosmolar effect or passive renal reabsorption of sodium.


Eligibility criteria:
inclusion criteria: * patients aged at least 18 years old * non-traumatic hsa * hyponatremia defined by a natremia less than 135 mmol / l and a high natriuresis, greater than 250 mmol / l despite well-managed saline intakes exclusion criteria: * severe cardiac decompensation (lvef \<30%) * severe hepatic cirrhosis (pt \<30%, ascites), known severe renal failure (gfr \<30ml / min / 1.73m²) * blood urea\> 25 mmol / l in the basal state * osmotherapy and diuretics in the last 48 hours * ongoing treatment with systemic corticosteroids * persons referred to in articles l1121-5 to l1121-8 of the csp corresponding to all protected persons: pregnant woman, parturient, nursing mother, person deprived of liberty by judicial or administrative decision, person subject to a legal protection measure. * patient not affiliated to a social security scheme * known hypersensitivity to any of the components of ergytonyl * contraindications to ergytonyl: taking curative anticoagulants, previously known and treated diabetic patients

Keywords: urea copeptine hyponatremia sah siadh
renal doppler in pediatric patients with idiopathic nephrotic syndrome

Conditions: Nephrotic Syndrome

Summary: the use of the renal resistive index in pediatric patient with idiopathic nephrotic syndrome to detect steroid resistance and to use it as a prognostic instrument of the progression of the disease.

renal doppler will be done for all children in supine and lateral positions using toshiba aplio ultrasound machine and renal resistive index will be measured (peak systolic velocity- end diastolic velocity/ peak systolic velocity) at diagnosis, after one month, 3 months and 6months, in which these values will be obtained by the ultrasound machine based on the computer algorithm. also the kidneys will be scanned firstly for length, width, cortical thickness and echogenicity.

Eligibility criteria:
inclusion criteria: * pediatric patients with primary nephrotic syndrome aged from 1 to 18 years exclusion criteria: * - patients with congenital nephrotic syndrome. * patients with secondary causes of nephrotic syndrome.

Keywords: renal doppler nephrotic syndrome steroid resistance
deep learning based early warning score in rapid response team activation

Conditions: Hospital Rapid Response Team; Hospital Medical Emergency Team

Summary: the objective of this study is to evaluate the safety and clinical usefulness of the deep learning based early warning score (dews).

sptts is the representative trigger tracking system. in addition to the conventional sptts, dews will be calculated at each time point by the previously developed algorithm. sptts and dews will be shown simulataneously on the screening board. the rapid response team performs the rescue activity as before, using both sptts and dews simultaneously. the alarm threshold setting of dews will be changed to 70 points, 75 points, and 80 points every month. the primary and secondary outcomes will be evaluated to compare sptts and dews (based on each threshold).

Eligibility criteria:
inclusion criteria: * patients admitted to general ward and monitored by in-hospital rapid response system exclusion criteria: * patients admitted to pediatric ward * patients in emergency room, intensive care unit, and operating room

Keywords: deep learning based early warning score rapid response team in-hospital cardiac arrest
effect of constraint induced movement therapy on burned dominant hand function

Conditions: Effect of Constraint Induced Movement Therapy on Burned Dominant Hand Function; Hand Burn

Summary: effect of constraint induced movement therapy on burned dominant hand function

effect of constraint induced movement therapy on burned dominant hand function we investigate the effect of constraint induced movement therapy on burned dominant hand function by using various measurement tools : * hand grip strength by hand held dynamometer * metacarpophalangeal joint flexion (mcp) by goniometer * function by michgan hand questionnaire a randomised controlled trial (2 groups) first group will receive constraint induced movement therapy (glove mitt) on sound hand . second group will receive the traditional treatment ( stretching - positioning ) we do the assessment before treatment and (4-8) after the start of treatment process.

Eligibility criteria:
inclusion criteria: * age of patient 20 to 35 * both male and female * suffer from dorsal hand dominant burn healed spontaneously or by graft * tbsa less than 20% * all patient active before injury. exclusion criteria: * patient with fracture * patient with crush injuries * patient with contralateral hand burn * patient with cardiovascular injury

Keywords: hand function - cimt - constraint - dominant hand function constraint induced movement therapy burn
mechanisms of intradialytic hypertension

Conditions: Renal Failure Chronic Requiring Hemodialysis; Haemodialysis-induced Symptom; Hypertension

Summary: patients with end-stage renal disease (esrd) are at significantly higher risk for death due to cardiovascular disease. those with paradoxical increases in blood pressure (bp) during hemodialysis (hd), defined as intradialytic hypertension (idh), are at even greater risk of cardiovascular mortality. this study seeks to determine the mechanisms that underlie idh, and whether mindfulness meditation might improve bp during dialysis in these patients. the investigators will first determine if increased adrenaline levels during volume removal contributes to idh. the investigators will then determine lack of suppression of adrenaline levels in the setting of a high bp also contributes to idh. this will be done by manipulating blood pressure by using small amounts of vasoactive drugs, and determining if an appropriate response in adrenaline levels occurs. lastly, the investigators will determine if an intradialytic mindfulness meditation program improves bp and adrenaline levels in esrd patients with idh.


Eligibility criteria:
inclusion criteria: * esrd patients on maintenance hemodialysis for at least 6 months, with increased blood pressure during hemodialysis exclusion criteria: * drug or alcohol abuse * any serious systemic disease that might influence survival * severe anemia with hgb level \<8 g/dl * clinical evidence of congestive heart failure * ejection fraction below 35% * myocardial infarction or cerebrovascular accident within the past six months * symptomatic heart disease determined by electrocardiogram, stress test, and/or history * treatment with central alpha agonists or monoamine oxidase (mao) inhibitors * peripheral neuropathy * autonomic dysfunction * pregnancy * surgery within the past 3 months
decoding chronic pain with fmri

Conditions: Chronic Back Pain

Summary: recent evidence suggests that chronic pain is associated with abnormal connectivity between brain regions associated with the processing of pain. we aim to test the diagnostic power of resting state functional magnetic resonance imaging (mri) to diagnose patients with chronic back pain. using new methods of image acquisition and analysis we aim to develop a computational method to correctly classify patients and matched control subjects.


Eligibility criteria:
inclusion criteria: * age 18-60 * pain \> 6months * right-handed * non-smoking * mechanical back pain exclusion criteria: * significant neurological or psychiatric disease * major systemic illness * mri exclusion criteria
autologous cord blood mononuclear cells for bronchopulmonary dysplasia in very preterm neonates

Conditions: Bronchopulmonary Dysplasia; Premature; Neonatal Death

Summary: rationale: pre-clinical animal studies provide robust evidence regarding the beneficial effect of cord blood-derived mononuclear cells (mncs) for experimental bronchopulmonary dysplasia (bpd). this single-center, non-randomized, controlled, blinded trial assessed the effect of a single intravenous infusion of autologous cord blood mncs (acbmncs) in preventing bpd in very preterm neonates, a high-risk population.


Eligibility criteria:
inclusion criteria: (1) born at the study hospital; (2) singleton birth; (3) ga \<32 weeks; (4) free of severe congenital anomalies or genetic syndromes; (5) without clinical chorioamnionitis; (6) the mother was negative for hepatitis b (hbsag and/or hbeag), hepatitis c (anti-hcv), syphilis, hiv (anti-hiv-1 and -2), and igm against cytomegalovirus, rubella, toxoplasma, and herpes simplex viruses; (7) consent was obtained from the parents or guardians; and (8) after processing, ucb cells were available.

Keywords: prevention bronchopulmonary dysplasia preterm cord blood mononuclear cells
confocal endomicroscopy during endoscopy

Conditions: Inflammatory Bowel Disease

Summary: the main objective of this study is to determine the role of epithelial cell homeostasis in the pathogenesis of intestinal diseases. background: alterations in intestinal barrier function may play a significant role in the pathogenesis of chronic intestinal diseases such as inflammatory bowel disease (ibd). the intestinal epithelium functions as a barrier to the luminal contents, thereby preventing undesirable solutes, micro-organisms and other luminal antigens from entering the body. confocal endomicroscopy has recently been shown that increased epithelial cell shedding may contribute to increased intestinal permeability, at least locally. in our study, we want to determine the contribution of epithelial cell shedding to intestinal permeability in vivo in patients with inflammatory bowel disease compared to controls. scope: in inflammatory bowel disease patients and controls (patients undergoing endoscopy for other indications). methods: we will perform confocal endoscopy during the patient's endoscopic procedure. procedure: the patient will receive intravenous fluorescein, followed by confocal imaging of the gastrointestinal tissue. the images are captured on the computer. the proposed study will provide important insights into epithelial cell shedding as a contributor to altered intestinal permeability.


Eligibility criteria:
inclusion criteria for patients includes: 1. subjects over 18 years of age. 2. subjects undergoing endoscopic procedures such as gastroscopy, colonoscopy, endoscopic retrograde cholangiopancreatography and endoscopic ultrasound will all be included. exclusion criteria: 1. under 18 years of age. 2. cognitively impaired. 3. residing in institutions (eg. prison, extended care facility) 4. employees of research(s)' organization 5. in emergency or life-threatening situations 6. have language barriers (eg. illiterate, not english-speaking, dysphasic) preventing adequate consent process 7. resides in another country

Keywords: crohn's disease ulcerative colitis dysplasia
marijuana's impact on alcohol motivation and consumption

Conditions: Alcohol Drinking; Marijuana

Summary: this laboratory study will employ a repeated measures experimental design to examine the effect of high (7.2% thc) and moderate (3% thc) dose of marijuana, relative to placebo, on alcohol craving and on behavioral economic measure of alcohol demand after exposure to alcohol cues, and on subsequent drinking in an alcohol choice task in which participants choose either to drink or receive monetary reinforcement for drinks not consume. the study will recruit 173 non-treatment seeking heavy episodic alcohol drinkers who smoke marijuana at least twice weekly.

this laboratory study will employ a repeated measures experimental design to examine the effect of high (7.2% thc) and moderate (3.0% thc) dose of marijuana, relative to placebo, on alcohol craving and on behavioral economic measure of alcohol demand after exposure to alcohol cues, and on subsequent drinking in an alcohol choice task in which participants choose either to drink or receive monetary reinforcement for drinks not consumed. moderators of the marijuana's effects on alcohol-related dependent variables will be tested: dsm5 alcohol use disorder severity, affective vulnerability, trait impulsivity, and working memory functioning. several empirically-determined mechanisms that may explain why marijuana may increase risk of alcohol relapse and help maintain heavy drinking will be tested as mediators of marijuana's effects on alcohol. the study will recruit 173 non-treatment seeking heavy episodic alcohol drinkers who smoke marijuana at least twice weekly to obtain the final sample of 150 with complete data (15% of attrition). participants will be tested at a baseline session and during three experimental sessions. investigators will collect blood samples for analysis of cannabinoid plasma levels and to examine marijuana-induced changes in hormones and other biomarkers potentially related to appetite, inflammation and stress. collection of these biomarkers would allow for a greater understanding about the mechanisms whereby marijuana may acutely increase alcohol motivation and use. the findings will inform researchers and clinicians about how marijuana acutely increases alcohol craving and consumption. the strategy of this proposal is to use the most comprehensive controlled test characterizing marijuana's putative effects on alcohol.

Eligibility criteria:
inclusion criteria: * age 21 to 44 * english-speaking * marijuana smoking in past month * report of current heavy episodic (binge) drinking * in good physical health and weighing \< 250 lbs * zero breath alcohol at each visit exclusion criteria: * history of seizures * smoking \>20 tobacco cigarettes per day * positive pregnancy test * nursing * positive urine toxicology screen for drugs other than cannabis * interest to quit or receive treatment for marijuana or alcohol use * meeting criteria for a current affective disorder (depression, or mania, panic disorder, and having psychotic symptoms as assessed by the scid)